[1]
|
Mehta, S.R., Yusuf, S., Peters, R.J., Bertrand, M.E., Lewis, B.S., Natarajan, M.K., et al. (2001) Effects of pre-treatment with clopidogrel and aspirin followed by long- term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. The Lancet, 358, 527-533. doi:10.1016/S0140-6736(01)05701-4
|
[2]
|
Angiolillo, D.J., Fernandez-Ortiz, A., Bernardo, E., Al-fonso, F., Macaya, C., Bass, T.A., et al. (2007) Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives. Journal of the American College of Cardiology, 49, 1505- 1516. doi:10.1016/j.jacc.2006.11.044
|
[3]
|
Wang, T.H., Bhatt, D.L. and Topol, E.J. (2006) Aspirin and clopidogrel resistance: An emerging clinical entity. European Heart Journal, 27, 647-654.
doi:10.1093/eurheartj/ehi684
|
[4]
|
Oh, I.Y., Park, K.W., Kang, S.H., Park, J.J., Na, S.H., Kang, H.J., et al. (2012) Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents. Heart, 98, 139-144.
doi:10.1136/hrt.2011.227272
|
[5]
|
Gurbel, P.A. and Tantry, U.S. (2007) Clopidogrel resis- tance? Thrombosis Research, 120, 311-321.
doi:10.1016/j.thromres.2006.08.012
|
[6]
|
Savi, P., Pereillo, J.M., Uzabiaga, M.F., Combalbert, J., Picard, C., Maffrand, J.P., et al. (2000) Identification and biological activity of the active metabolite of clopidogrel. Thrombosis and Haemostasis, 84, 891-896.
|
[7]
|
Mauri, L., Hsieh, W.H., Massaro, J.M., Ho, K.K., D’Ago-stino, R. and Cutlip, D.E. (2007) Stent thrombosis in randomized clinical trials of drug-eluting stents. The New England Journal of Medicine, 356, 1020-1029.
doi:10.1056/NEJMoa067731
|
[8]
|
Chaudhry, A.S., Kochhar, R. and Kohli, K.K. (2009) Importance of CYP2C19 genetic polymorphism in the eradication of Helicobacter pylori in north Indians. Indian Journal of Medical Research, 130, 437-443.
|
[9]
|
Geisler, T., Langer, H., Wydymus, M., G?hring, K., Zürn, C. and Bigalke, B. (2006) Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. European Heart Journal, 27, 2420-2425. doi:10.1093/eurheartj/ehl275
|
[10]
|
Hochholzer, W., Trenk, D., Bestehorn, H.P., Fischer, B., Valina, C.M. and Ferenc, M. (2006) Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrelon early clinical outcome of elective coronary stent placement. Journal of the American College of Cardiology, 48, 1742-1750. doi:10.1016/j.jacc.2006.06.065
|
[11]
|
Lev, E.I., Patel, R.T., Maresh, K.J., Guthikonda, S., Granada, J., DeLao, T. and Bray, P.F., (2006) Aspirin and clopidogrel drug response in patients undergoing percu-taneous coronary intervention: The role of dual drug resistance. Journal of the American College of Cardiology, 47, 27-33. doi:10.1016/j.jacc.2005.08.058
|
[12]
|
Gurbel, P.A., Bliden, K.P., Hayes, K.M., Yoho, J.A., Herzog, W.R. and Tantry, U.S. (2005) The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. Journal of the American College of Cardiology, 45, 1392-1396.
doi:10.1016/j.jacc.2005.01.030
|
[13]
|
Dziewierz, A., Dudek, D., Heba, G., Rakowski, T., Mielecki, W. and Dubiel, J.S. (2005) Interindividualvari-ability in response to clopidogrel in patients with coronary artery disease. Kardiologia Polska, 62, 108-117.
|
[14]
|
Serebruany, V.L., Steinhubl, S.R., Berger, P.B., Malinin, A.I., Bhatt, D.L. and Topol, E.J. (2005) Variability in platelet responsiveness to clopidogrel among 544 individuals. Journal of the American College of Cardiology, 45, 246-251. doi:10.1016/j.jacc.2004.09.067
|
[15]
|
Michelson, A.D., Linden, M.D., Furman, M.I., Li, Y., Barnard, M.R., Fox, M.L., et al. (2007) Evidence that preexistent variability in platelet response to ADP accounts for “clopidogrel resistance”. Journal of Thrombo-sis and Haemostasis, 5, 75-81.
doi:10.1111/j.1538-7836.2006.02234.x
|
[16]
|
Xie, H.G., Stein, C.M., Kim, R.B., Wilkinson, G.R., Flockhart, D.A. and Wood, A.J. (1999) Allelic, genotypic and phenotypic distributions of S-mephenytoin 4’-hydro- xylase (CYP2C19)in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics, 9, 539-549. doi:10.1097/00008571-199910000-00001
|
[17]
|
Goldstein, J.A., Ishizaki, T., Chiba, K., Morais, S.M., Bell, D., Krahn, P.M., et al. (1997) Frequencies of the defective CYP2C19 alleles responsible for the mepheny- toin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics, 1, 59-64.
doi:10.1097/00008571-199702000-00008
|
[18]
|
Takakubo, F., Kuwano, A. and Kondo, I. (1996) Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese. Pharmacogenetics, 6, 265-267.
doi:10.1097/00008571-199606000-00011
|
[19]
|
Nowak, M.P., Sellers, E.M. and Tyndale, R.F. (1998) Canadian native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies. Clinical Pharmacology & Therapeutics, 64, 378-383.
doi:10.1016/S0009-9236(98)90068-6
|
[20]
|
Ruas, J.L. and Lechner, M.C. (1997) Allele frequency of CYP2C19 in a Portuguese population. Pharmacogenetics, 7, 333-335. doi:10.1097/00008571-199708000-00009
|
[21]
|
Chang, M., Dahl, M.L., Tybring, G., Tharson, E. and Bertilsson, L. (1995) Use of omeprazole as aprobe drug for CYP2C19 phenotype in Swedish Caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics, 5, 358-363.
doi:10.1097/00008571-199512000-00004
|
[22]
|
Collet, J.P., Hulot, J.S., Pena, A., Villard, E., Esteve, J.B., Silvain, J., et al. (2009) CytochromeP450 2C19 poly-morphism in young patients treated with clopidogrel after myocardial infarction: A cohort study. Lancet, 373, 309-317. doi:10.1016/S0140-6736(08)61845-0
|
[23]
|
Schuldiner, A.R., O’Connell, J.R., Bliden, K.P., Gandhi, A., Ryan, K., Horenstein, R.B., et al. (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect andclinical efficacy of clopidogrel. The Journal of the American Medical Association, 302, 849-857.
doi:10.1001/jama.2009.1232
|
[24]
|
Sibbing, D., Stegherr, J., Latz, W., Koch, W., Mehilli, J., Dorrler, K., et al. (2009) Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. European Heart Jour- nal, 30, 916-922. doi:10.1093/eurheartj/ehp041
|
[25]
|
Mega, J.L., Close, S.L., Wiviott, S.D., Wiviott, S.D., Shen, L., Hockett, R.D., et al. (2009) Cytochrome P450 polymorphism and response to clopidogrel. The New England Journal of Medicine, 360, 354-362.
doi:10.1056/NEJMoa0809171
|
[26]
|
Trenk, D., Hochholzer, W., Fromm, M.F., Chialda, L.E., Pahi, A., Valina, C.M., et al. (2008) Cytochrome P450 2C19 681G>A polymorphism and high onclopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. Journal of the American College of Cardiology, 51, 1925-1934.
doi:10.1016/j.jacc.2007.12.056
|
[27]
|
Jinnai, T., Horiuchi, H., Makiyama, T., Tazaki, J., Tada, T., Akao, M., et al. (2009) Impact of CYP2C19 polymorphism on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan. Circulation Journal, 73, 1498-1503. doi:10.1253/circj.CJ-09-0019
|